Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial function

Bajpeyi, 2011, Skeletal muscle mitochondrial capacity and insulin resistance in type 2 diabetes, J Clin Endocrinol Metab, 96, 1160, 10.1210/jc.2010-1621 Patti, 2003, Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1, Proc Natl Acad Sci U S A, 100, 8466, 10.1073/pnas.1032913100 Ruotolo, 2002, Dyslipidemia of the metabolic syndrome, Curr Cardiol Rep, 4, 494, 10.1007/s11886-002-0113-6 Shulman, 2000, Cellular mechanisms of insulin resistance, J Clin Invest, 106, 171, 10.1172/JCI10583 Bajpeyi, 2012, Effect of short-term exercise training on intramyocellular lipid content, Appl Physiol Nutr Metab, 37, 822, 10.1139/h2012-051 Jacob, 1999, Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects, Diabetes, 48, 1113, 10.2337/diabetes.48.5.1113 Kelley, 1999, Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss, Am J Phys, 277, E1130 Corpeleijn, 2008, Impaired skeletal muscle substrate oxidation in glucose-intolerant men improves after weight loss, Obesity (Silver Spring), 16, 1025, 10.1038/oby.2008.24 Ukropcova, 2007, Family history of diabetes links impaired substrate switching and reduced mitochondrial content in skeletal muscle, Diabetes, 56, 720, 10.2337/db06-0521 Day, 1999, Thiazolidinediones: a new class of antidiabetic drugs, Diabet Med, 16, 179, 10.1046/j.1464-5491.1999.00023.x Bogacka, 2005, Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo, Diabetes, 54, 1392, 10.2337/diabetes.54.5.1392 Goldberg, 2005, A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia, Diabetes Care, 28, 1547, 10.2337/diacare.28.7.1547 Chiquette, 2004, A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors, Arch Intern Med, 164, 2097, 10.1001/archinte.164.19.2097 Deeg, 2008, Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies, PPAR Res, 2008, 520465, 10.1155/2008/520465 Wallace, 2004, An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study, Diabet Med, 21, 568, 10.1111/j.1464-5491.2004.01218.x Nagashima, 2005, Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus, J Clin Invest, 115, 1323, 10.1172/JCI200523219 Mayerson, 2002, The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes, Diabetes, 51, 797, 10.2337/diabetes.51.3.797 Bajaj, 2010, Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus, J Clin Endocrinol Metab, 95, 1916, 10.1210/jc.2009-0911 Coletta, 2009, Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial, Diabetologia, 52, 723, 10.1007/s00125-008-1256-9 Rabol, 2010, Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes, Diabetes Obes Metab, 12, 806, 10.1111/j.1463-1326.2010.01237.x Bajpeyi, 2011, Skeletal muscle mitochondrial capacity and insulin resistance in type 2 diabetes, J Clin Endocrinol Metab, 96, 1160, 10.1210/jc.2010-1621 Conley, 2013, Higher mitochondrial respiration and uncoupling with reduced electron transport chain content in vivo in muscle of sedentary versus active subjects, J Clin Endocrinol Metab, 98, 129, 10.1210/jc.2012-2967 Conley, 1997, Activation of glycolysis in human muscle in vivo, Am J Phys, 273, C306, 10.1152/ajpcell.1997.273.1.C306 Blei, 1993, Individual variation in contractile cost and recovery in a human skeletal muscle, Proc Natl Acad Sci U S A, 90, 7396, 10.1073/pnas.90.15.7396 Jubrias, 2003, Acidosis inhibits oxidative phosphorylation in contracting human skeletal muscle in vivo, J Physiol, 553, 589, 10.1113/jphysiol.2003.045872 Conley, 2000, Oxidative capacity and ageing in human muscle, J Physiol, 526, 203, 10.1111/j.1469-7793.2000.t01-1-00203.x Larson-Meyer, 2006, Muscle-associated triglyceride measured by computed tomography and magnetic resonance spectroscopy, Obesity (Silver Spring), 14, 73, 10.1038/oby.2006.10 Larson-Meyer, 2010, Feasibility of assessing liver lipid by proton magnetic resonance spectroscopy in healthy normal and overweight prepubertal children, Diabetes Technol Ther, 12, 207, 10.1089/dia.2009.0069 Larson-Meyer, 2011, Intrahepatic and intramyocellular lipids are determinants of insulin resistance in prepubertal children, Diabetologia, 54, 869, 10.1007/s00125-010-2022-3 Cefalu, 2010, Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus, Metabolism, 59, 755, 10.1016/j.metabol.2009.09.023 Larson-Meyer, 2002, Influence of endurance running and recovery diet on intramyocellular lipid content in women: a 1H NMR study, Am J Physiol Endocrinol Metab, 282, E95, 10.1152/ajpendo.2002.282.1.E95 Naressi, 2001, Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals, Comput Biol Med, 31, 269, 10.1016/S0010-4825(01)00006-3 Galgani, 2008, Metabolic flexibility in response to glucose is not impaired in people with type 2 diabetes after controlling for glucose disposal rate, Diabetes, 57, 841, 10.2337/db08-0043 Lillioja, 1988, Obesity and insulin resistance: lessons learned from the Pima Indians, Diabetes Metab Rev, 4, 517, 10.1002/dmr.5610040508 Kelley, 1994, Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus, J Clin Invest, 94, 2349, 10.1172/JCI117600 Sparks, 2009, Relation of adipose tissue to metabolic flexibility, Diabetes Res Clin Pract, 83, 32, 10.1016/j.diabres.2008.09.052 Scherbaum, 2002, Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study, Horm Metab Res, 34, 589, 10.1055/s-2002-35421 Herz, 2003, A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus, Clin Ther, 25, 1074, 10.1016/S0149-2918(03)80068-1 Rasouli, 2005, Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue, Am J Physiol Endocrinol Metab, 288, E930, 10.1152/ajpendo.00522.2004 Bajaj, 2003, Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes, Diabetes, 52, 1364, 10.2337/diabetes.52.6.1364 Ravikumar, 2008, Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content, Diabetes, 57, 2288, 10.2337/db07-1828 Bourlier, 2013, Enhanced glucose metabolism is preserved in cultured primary myotubes from obese donors in response to exercise training, J Clin Endocrinol Metab, 98, 3739, 10.1210/jc.2013-1727 Moro, 2008, Determinants of intramyocellular triglyceride turnover: implications for insulin sensitivity, Am J Physiol Endocrinol Metab, 294, E203, 10.1152/ajpendo.00624.2007 Kranebitter, 2010, Pioglitazone has direct effects on insulin sensitivity and intracellular lipid content in L6 skeletal muscle cells, Horm Metab Res, 42, 987, 10.1055/s-0030-1265224 Teranishi, 2007, Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus, Metabolism, 56, 1418, 10.1016/j.metabol.2007.06.005 Cusi, 2016, Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial, Ann Intern Med, 165, 305, 10.7326/M15-1774 Sanyal, 2010, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, N Engl J Med, 362, 1675, 10.1056/NEJMoa0907929 Petersen, 2004, Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes, N Engl J Med, 350, 664, 10.1056/NEJMoa031314 Simoneau, 1999, Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss, FASEB J, 13, 2051, 10.1096/fasebj.13.14.2051 Mathieu-Costello, 2003, Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal, Metabolism, 52, 540, 10.1053/meta.2002.50108 Skov, 2008, Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome, PLoS One, 3, e2466, 10.1371/journal.pone.0002466 Amara, 2007, Mild mitochondrial uncoupling impacts cellular aging in human muscles in vivo, Proc Natl Acad Sci U S A, 104, 1057, 10.1073/pnas.0610131104